



## Novel Approaches to Hematologic Malignancies by Immunotherapy

Guest Editor:

**Dr. Yosuke Minami**

National Cancer Center Hospital  
East, Kashiwa 277-8577, Chiba,  
Japan

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editor

Dear Colleagues,

The landscape of immunotherapy for the treatment hematologic malignancies (HMs) has become crowded in light of new modalities. Some HMs can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/ programmed cell-death protein 1 ligand 1 (PD-L1) immune checkpoint. Therapeutic antibodies that block the PD-1-PD-L1 axis or other types of checkpoint inhibitors induce durable clinical responses against a growing list of various HMs. Chimeric antigen receptor (CAR) T cells, bispecific T-cell engagers (BiTEs), and antibody-drug conjugates (ADCs) are also promising candidates. In this issue, we would like to show the novel immunotherapy in translational research and clinical development for the treatment of HMs.

Dr. Yosuke Minami  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Maurizio Battino

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

## Contact Us

---

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI